Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.
Year: 2016
Type: article
Source: Europe PMC (PubMed Central)
Author: Lisa A Raedler
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2400060828